Mabtas N 100mg Injection
Marketer
Intas Pharmaceuticals Ltd
Salt Composition
Rituximab (100mg)
Overview Mabtas N 100mg Injection
Rituximab 100mg Injection is indicated for various conditions, including non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis. Administration is strictly by injection under a physician's direct supervision, with dosage and frequency determined individually by your doctor based on your specific diagnosis and response. Precise adherence to the prescribed regimen is crucial, as incorrect usage or overdosage can lead to severe adverse reactions. While therapeutic effects may not be immediately apparent, typically manifesting after several weeks or months, discontinuation should only occur under medical guidance. Common side effects encompass headache, fatigue, swelling, infections, and alopecia. A reduction in blood cell counts (both red and white) is possible, enhancing vulnerability to infections. Regular blood monitoring, including hepatitis B screening, is essential. Prior to commencing treatment, inform your physician of any pre-existing heart or liver conditions, planned surgical procedures or vaccinations, and all concurrent medications, as drug interactions are possible. This medication is contraindicated during pregnancy and lactation; reliable contraception is strongly advised for both partners throughout the treatment period.
Primary Ingredients of Mabtas N 100mg Injection
No text provided to rephrase.
Uses of Mabtas N 100mg Injection
Chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and non-Hodgkin lymphoma.
Major Benefits of Mabtas N 100mg Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Mabtas N 100mg Injection:
- Headache
- Weakness
- Infection
- Chills
- Decreased white blood cell count (neutrophils)
- Fever
- Infusion site reaction
- Lymphopenia
- Abdominal pain
- Back pain
How to use Mabtas N 100mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Mabtas N 100mg Injection works:
Nivolumab 100mg injection is a targeted therapy utilizing a monoclonal antibody to neutralize the aberrant activity of B lymphocytes in rheumatoid arthritis and selected malignancies.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when using Mabtas N 100mg Injection concurrently with alcohol. Seek medical advice.
PregnancyCONSULT YOUR DOCTOR
Using Mabtas N 100mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the unborn child. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Administration of Mabtas N 100mg Injection while breastfeeding is likely safe. Available human data indicates minimal risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Mabtas N 100mg Injection on driving ability is unknown. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
The use of Mabtas N 100mg Injection in individuals with kidney disease is likely safe. Preliminary findings indicate dose modification may be unnecessary, however, physician consultation is advised.
LiverCONSULT YOUR DOCTOR
Data on Mabtas N 100mg Injection's use in individuals with hepatic impairment is scarce. Physician consultation is advised. Mabtas N 100mg Injection is contraindicated in patients with active liver disease or a history of viral hepatitis due to the risk of infection recurrence.
What if you forget to take Mabtas N 100mg Injection :
Should you forget a scheduled dose of Mabtas N 100mg Injection, seek advice from your physician.
Facts to Know About Mabtas N 100mg Injection
| Label | Value |
|---|---|
| Chemical Category | Monoclonal antibody |
| Developing Habits | No. |
| Treatment Category | Cancer Treatments |
| Action Class | CD20-targeting agent |
3,018 People bought this recently